Earnings History Data for Viridian Therapeutics, Inc. (VRDN) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Viridian Therapeutics, Inc.
Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12-11-2024 | PM | VRDN | Viridian Therapeutics, Inc. | 1,580 | -1.15 | -1.11 | -1.09 | Viridian Therapeutics GAAP EPS of -$1.15 misses by $0.08, revenue of $0.09M beats by $0.04M [11/12/2024 7:25 AM] |
22.55 | -3.16 (-12.27%) |
27.00 | 1.29 (5.02%) |
11.40 - 27.20 | 2,333,305 | 860,000 | 74,131 | ||
| 08-08-2024 | PM | VRDN | Viridian Therapeutics | 968.00 | -1.02 | -0.87 | 0.00 | 15.09 | -0.31 (-2.01%) |
15.40 | 0.0 (0.00%) |
10.93 - 24.18 | 538,650 | 1,200,000 | 477 | |||
|
|
||||||||||||||||||
| 08-05-2024 | PM | VRDN | Viridian Therapeutics, Inc. | 978.55 | -0.79 | -1.07 | -1.61 | Viridian Therapeutics GAAP EPS of -$0.79 beats by $0.28, revenue of $0.07M misses by $0.01M [5/8/2024 7:22 AM] |
14.90 | -0.24 (-1.59%) |
14.90 | 0.0 (0.00%) |
10.93 - 28.35 | 985,014 | 810,000 | 17,332 | ||
| 27-02-2024 | PM | VRDN | Viridian Therapeutics | 987.00 | -1.35 | -1.08 | 0.00 | Viridian Therapeutics GAAP EPS of -$1.35 [2/28/2024 1:29 AM] |
20.14 | 0.54 (2.73%) |
19.80 | 0.19 (0.97%) |
10.93 - 33.51 | 1,718,938 | 780,000 | 501 | ||
| 13-11-2023 | PM | VRDN | Viridian Therapeutics, Inc. | 593.48 | -1.09 | -1.22 | -0.86 | Viridian Therapeutics GAAP EPS of -$1.09 beats by $0.08, revenue of $0.07M misses by $0.03M [11/14/2023 1:33 AM] |
15.18 | 1.19 (8.47%) |
14.30 | 0.31 (2.22%) |
10.93 - 39.00 | 1,112,859 | 960,000 | 886 | ||
| 08-08-2023 | AH | VRDN | Viridian Therapeutics | 815.00 | -1.27 | -1.26 | 0.00 | Viridian Therapeutics GAAP EPS of -$1.27 in-line, revenue of $0.07M misses by $0.13M [8/8/2023 5:21 PM] |
19.29 | 0.54 (2.88%) |
18.38 | -0.37 (-1.97%) |
13.45 - 39.00 | 742,893 | 670,000 | 1,625 | ||
| 09-05-2023 | AH | After the close (May 9) |
VRDN | Viridian Therapeutics, Inc. | 1,130 | -1.61 | 1.00 | -0.98 | Viridian Therapeutics GAAP EPS of -$1.61 misses by $0.59, revenue of $0.1M in-line [5/9/2023 4:58 PM] |
25.36 | -0.32 (-1.25%) |
24.60 | -1.08 (-4.21%) |
9.66 - 39.00 | 845,802 | 610,000 | 12,229 | |
| 08-03-2023 | PM | 7:00 AM ET (Mar 8) |
VRDN | Viridian Therapeutics, Inc. | 1,320 | -1.13 | -0.72 | -1.32 | Viridian Therapeutics GAAP EPS of -$1.13 misses by $0.40, revenue of $0.1M misses by $0.36M [3/8/2023 7:02 AM] |
29.43 | -3.49 (-10.60%) |
31.41 | -1.51 (-4.59%) |
9.47 - 39.00 | 1,429,926 | 410,000 | 12,757 | |
| 14-11-2022 | PM | 7:00 AM ET (Nov 14) |
VRDN | Viridian Therapeutics, Inc. | 789.80 | -0.86 | -0.87 | -1.25 | Viridian Therapeutics GAAP EPS of -$0.86 beats by $0.12, revenue of $1.19M beats by $0.93M [11/14/2022 7:12 AM] |
20.27 | -0.24 (-1.15%) |
20.51 | 0.0 (0.00%) |
9.47 - 26.22 | 789,198 | 410,000 | 16,294 | |
| 15-08-2022 | PM | 7:00 AM ET (Aug 15) |
VRDN | Viridian Therapeutics, Inc. | 362.22 | -1.06 | -0.86 | -2.21 | Viridian Therapeutics GAAP EPS of -$1.06 misses by $0.17, revenue of $0.26M beats by $0.03M [8/15/2022 7:05 AM] |
21.91 | 7.18 (48.74%) |
19.18 | 4.45 (30.21%) |
9.47 - 25.38 | 11,710,629 | 350,000 | 834,896 | |
|
||||||||||||||||||
| 12-05-2022 | AH | 4:05 PM ET (May 12) |
VRDN | Viridian Therapeutics, Inc. | 289.90 | -0.98 | -0.92 | -2.91 | Viridian Therapeutics GAAP EPS of $0.98, revenue of $0.22M [5/12/2022 4:20 PM] |
13.51 | 2.95 (27.94%) |
10.56 | 0.0 (0.00%) |
9.47 - 22.00 | 387,598 | 320,000 | 588 | |
| 10-03-2022 | AH | 4:05 PM ET (Mar 10) |
VRDN | Viridian Therapeutics, Inc. | 392.09 | -1.32 | -1.15 | -5.31 | Viridian Therapeutics GAAP EPS of -$1.32, revenue of $0.21M [3/10/2022 4:12 PM] |
20.29 | 1.25 (6.57%) |
0.0 | 0.0 (0.00%) |
10.44 - 22.00 | 101,838 | 130,000 | 0 | |
|
||||||||||||||||||
| 04-11-2021 | AH | VRDN | Viridian Therapeutics | 168.00 | -1.25 | -1.19 | 0.00 | Viridian Therapeutics reports Q3 results [11/4/2021 5:36 PM] |
18.86 | 0.77 (4.26%) |
0.0 | 0.0 (0.00%) |
10.44 - 25.67 | 81,915 | 80,000 | 0 | ||
| 06-05-2021 | AH | 4:05 PM ET (May 6) |
VRDN | Viridian Therapeutics, Inc. | 0.00 | -2.91 | -0.61 | 0.00 | Viridian Therapeutics reports Q1 results [5/6/2021 5:12 PM] |
17.53 | 0.17 (0.98%) |
0.0 | 0.0 (0.00%) |
7.08 - 25.67 | 5,457 | 60,000 | 0 | |
| 25-03-2021 | AH | After the close (Mar 25) |
VRDN | Viridian Therapeutics, Inc. | 0.00 | -5.31 | -1.27 | 0.00 | Viridian Therapeutics reports Q4 results [3/25/2021 4:38 PM] |
17.97 | 0.70 (4.02%) |
17.01 | -0.26 (-1.51%) |
5.54 - 25.67 | 51,968 | 20,000 | 130 | |